TEVAR is the accepted first-line strategy for complicated type B aortic dissection, and its indications are expanding to include subacute asymptomatic and chronic phases to prevent aneurysmal expansion.
Answers are grounded in this paper and cite their sources.
Supports broader TEVAR use in type B dissection; leaves open need for RCTs to define optimal timing and outcomes.
The management of type B aortic dissection is undergoing profound changes with timely TEVAR accepted as first-line strategy in the setting of complicated dissection; with recent technological advances and in experienced hands this intervention is considered safe and life-saving. With the ability to remodel the dissected aorta as a result of scaffolding even pre-emptive endovascular treatment is being considered and supported by long-term stability and often prevention of aneurysmal expansion. This insight and a growing number of silent risk conditions (resistant hypertension, partial false lumen thrombosis) may lower the threshold for TEVAR in asymptomatic patients in the subacute phase. In the chronic phase of a type B dissection patients are usually free of symptoms, however, with the expanding false lumen at risk of rupture. Advanced TEVAR options (including branches and fenestrations) are likely to be used more often than open surgical replacement of such aneurysmatic segment of the dissected aorta in that chronic phase. All dissection patients should be offered lifelong surveillance.
No takes yet. Share an insight, caveat, or question.
Nienaber et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: